News

Categories

October 31, 2024

Zymeworks Provides Corporate Update and
Reports Third Quarter 2024 Financial Results

October 29, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

October 25, 2024

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

October 21, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

October 10, 2024

Zymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

October 9, 2024

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

October 8, 2024

Dr. Raffaele Colombo Honored as a PharmaVoice 100 Winner

October 7, 2024

Zymeworks Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer Annual Meeting

September 18, 2024

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

September 16, 2024

Zymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

September 9, 2024

Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ESMO 2024

August 22, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences